API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
Other Listed Suppliers
0
0
Details:
The portfolio to be divested includes a variety of over-the-counter medicines and health products. TCHC’s strong regional brands include Alinamin, and Benza.
Lead Product(s): Fursultiamine
Therapeutic Area: Ophthalmology Product Name: Alinamin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Blackstone Life Sciences
Deal Size: $2,300.0 million Upfront Cash: Undisclosed
Deal Type: Divestment August 24, 2020